To evaluate & compare the in-vivo safety and efficacy of a skin care formulation versus placebo in terms of reduction in fine lines and wrinkles, reduction in dark spots, skin firmness, skin brightness, skin water barrier function and skin moisturization on healthy human subjects - Nil

KOP research centre private limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Indian female subjects
•2.Healthy subjects
•3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
•4.Subject having Crows feet wrinkle
•5.Subject having dark spots

•1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
•2. Having refused to give her/his assent by not signing the consent form
•3. Taking part in another study liable to interfere with this study
•4. Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
•5. Having a progressive asthma (either under treatment or last fit in the last 2 years)
•6. Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis)
•7. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
•8. Being epileptic.
•9. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
•10. Having cutaneous hypersensitivity.
•11. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
•12. Having undergone a surgery requiring a general anesthetic of more than one hour in the past 6

发起方

KOP research centre private limited